Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.
Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
You can also call our clinical trial information center at 1-888-577-8839 to learn more.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab in Participants With High Risk Non-muscle Invasive Bladder Cancer||057||Bladder Cancer||Phase 2||Recruiting|
|A Study of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer||045||Urothelial Cancer||Phase 3||Active, not recruiting|
|Study of Pembrolizumab in Participants With Advanced Urothelial Cancer||052||Urothelial Cancer||Phase 2||Active, not recruiting|
|Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma||361||Urothelial Carcinoma Associated 1 RNA, Human||Phase 3||Active, not recruiting|
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.